Posted on

cbd withdrawal

Copyright © 2020 Elsevier Inc. All rights reserved.

Methods: Thirty volunteers were randomized to receive 750 mg of a plant-derived pharmaceutical formulation of highly purified CBD in oral solution (100 mg/mL; Epidiolex® in the United States and Epidyolex® in Europe) twice daily (b.i.d.) for 4 weeks (Part 1) followed by 2 weeks of 750 mg b.i.d. CBD (Part 2, Arm 1) or matched placebo (Part 2, Arm 2). All volunteers completed the Cannabis Withdrawal Scale (CWS) and the 20-item Penn Physician Withdrawal Checklist (PWC-20) on days -1, 21, 28, 31, 35, 42, and at follow-up.

Conclusion: In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.

Rationale: The rationale of this study was to assess occurrence of withdrawal symptoms induced by abrupt cessation of cannabidiol (CBD) after prolonged administration in healthy volunteers.

Conflict of interest statement

Keywords: Cannabidiol; Cannabinoid; Drug withdrawal; Epilepsy; Seizure.

Results: Median CWS and PWC-20 scores slightly decreased from Part 1 to Part 2. Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2. Median PWC-20 scores were 0.0 (out of a possible 60) in both arms. Twenty-nine (97%) volunteers in Part 1 reported all-causality treatment-emergent adverse events (AEs); the most commonly reported was diarrhea (63%). In Part 2, Arm 1, 6 (67%) volunteers reported all-causality AEs; the most commonly reported was diarrhea (44%). In Part 2, Arm 2, 9 (75%) volunteers reported all-causality AEs; the most commonly reported was headache (58%). Nine volunteers withdrew because of AEs in Part 1; 1 withdrew in Part 2, Arm 2, because of an AE that began in Part 1. Four severe AEs were reported in Part 1; the remainder were mild or moderate. No serious AEs were reported.

Declaration of competing interest All authors met the International Committee of Medical Journal Editors authorship criteria. Neither honoraria nor payments were made for authorship. Lesley Taylor was an employee of GW Research Ltd. at the time the work was completed. Julie Crockett is an employee of GW Research Ltd. and has share options in the company. Bola Tayo is an employee of GW Research Ltd. and owns shares in the company. Daniel Checketts is an employee of GW Research Ltd. Kenneth Sommerville was an employee of Greenwich Biosciences, Inc. at the time the work was completed.

Cbd withdrawal

Unlike many remedies and pharmaceuticals, cannabidiol doesn’t make you dependent, so it doesn’t pose any abuse risks. According to the World Health Organization, CBD is a safe alternative for many medications, including painkillers.

Cannabidiol has shown positive results in preventing some types of cancer, promoting cancer cell destruction, and suppressing cell growth. In fact, for some patients, CBD is more effective than other treatments such as chemotherapy.

It can also help you get rid of the issues or symptoms that keep you awake, for example, stress, anxiety, or pain.

CBD Topicals

Stress and anxiety can be a big problem for people struggling with substance addiction. It is one of those never-ending feelings and can significantly impact your quality of life.

However, in almost every medical condition, the endocannabinoid system is greatly affected. CBD helps to balance and regulate the system by imitating the compound’s effects. As a result, it helps prevent any major breakdown in your body and brain, leading to disruption in your physical and mental functioning.

CBD and Pain

Also, most prescribed anti-depressants and painkillers are opiates, and the chances of forming an addiction are high. CBD can help relieve anxiety, stress, and pain without the potential of producing the same side effects.

As you can assume, many people are using CBD to help with their physical and mental health issues. However, they wonder what happens after they stop consuming cannabidiol.